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statistically heterogeneous. ConClusions: Medical doctors were more requested 
than dentists and hospitals. The use of health services was more concentrated in 
developed areas. The pooled results of meta-analysis suggest representativeness 
of Brazilian population for the last decade.
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objeCtives: Four hurdles associated with economic evaluations in health care 
interventions were identified and examined in a previous published literature 
review. These hurdles include (i) ‘Ignoring the impact of condition-specific out-
comes’, (ii) ‘Ignoring the impact of QoL externalities’, (iii) ‘Calculation of costs 
from a too narrow perspective’ and (iv) ‘The lack of well-described & standardized 
interventions’. This study aims to determine how healthcare providers experi-
ence and deal with these hurdles in practice and what solutions or new insights 
they would suggest. Methods: Fourteen general practitioners (GPs), who were 
participating in a health care intervention in Flanders, were interviewed about 
the four described hurdles in a semi-structured way. A thematic framework was 
developed to enable the qualitative analysis. Results: The interviews revealed 
a clear need to tackle these hurdles. GPs confirmed that more condition-specific 
outcomes in economic evaluations are needed, especially in the field of mental 
health and stress. The proposed dimensions for the condition-specific question-
naires varied however between the GPs. With respect to QoL externalities, GPs 
confirmed that health care interventions have an impact on the environment of 
the patient (friends and family). There was however no consensus on how this 
impact of QoL externalities should be taken into account. Besides health care 
costs, the impact of health care interventions on work productivity, the patients’ 
social life (culture, sport) and other items such as traffic accidents must be incor-
porated to provide an overall picture. Standardization appears to be of limited 
added value for most of the interviewed GPs because they need a certain degree 
of freedom to interpret the intervention. Lack of time has been claimed by GPs as 
the biggest issue for standardization of health care interventions. ConClusions: 
This qualitative research demonstrated that these hurdles occur in practice and 
contributes to improve the methodological quality of economic evaluations of 
health care interventions.
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objeCtives: Adherence to antidiabetic treatment is a crucial issue in type 2 
diabetes management. Depression negatively influences adherence to self-care 
recommendations, such as diet, physical activity and drug therapy. The objectives 
of this study are to measure the association between depression and discontinu-
ation with antidiabetic drugs (ADs), among new users of oral antidiabetic drugs 
(OADs) and to estimate factors associated with discontinuation among these new 
users with depression. Methods: We used administrative claims data of the 
public health insurance plan in Quebec, Canada, to identify an adult cohort (≥ 18 
years) of new OAD users free of depression between 2000 and 2006. We followed 
patients from OAD initiation up to AD discontinuation, ineligibility to the pub-
lic drug plan, death, or the end of the study, i.e. December 31, 2008, whichever 
came first. A Cox regression model with depression as a time-dependent variable 
was used to compute the adjusted hazard ratio (AHR) of discontinuation. A Cox 
regression models was used to identify factors associated with discontinuation in 
the sub-cohort of patients with depression. Results: We identified 114,366 new 
OAD users, of which 4,808 were diagnosed with depression during follow-up. The 
median time from OAD treatment initiation to discontinuation was 2.4 years: 55.4 
% of patients with depression versus 44.5% without depression discontinued their 
treatment during follow-up. The AHR of discontinuation with ADs was 1.52 (95% 
confidence interval [CI]: 1.41-1.63). Among the 4,808 patients with depression, 
independent factors associated with discontinuation included starting treatment 
with other drugs than metformin (especially polytherapy with insulin), being pre-
scribed the first OAD by a specialist (vs a general practitioner), and younger age 
at OAD initiation (< 45 years). ConClusions: Patients with depression are more 
likely to discontinue their treatment. Physicians should target patients at risk 
for discontinuation in order to improve persistence with antidiabetic drugs and 
diabetes management.
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objeCtives: With the ageing of the Singapore population, the incidence of falls 
and its consequences will increase unless effective interventions are implemented. 
This evaluation assesses the effectiveness of the Stepping Out program in pre-
venting falls, improving overall physical performance, general well-being and falls 
efficacy. Methods: Stepping Out is a 52-week program for community-dwelling 
elderly residents. Participants were risk-stratified prior to receiving physical exer-
cises, education, and referrals to healthcare providers and community partners. 
The first 3-months were supervised by nurses and physiotherapists, and the next 
9-months by community volunteers. The evaluation utilized a prospective cohort 
design with waitlisted controls. Eligible participants were invited into the program 
one year before receiving the intervention, during which data collected for that 
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objeCtives: This study aimed to provide insight into the current and potential use 
of economic evaluations in Dutch healthcare decision-making and to identify bar-
riers and facilitators to the use of such studies. Methods: Interviews containing 
semi-structured and structured questions were conducted among Dutch healthcare 
decision-makers. Responses to the semi-structured questions were analyzed using a 
constant comparative approach. For the responses to the structured questions, sum-
mary statistics were prepared. Results: Sixteen healthcare decision-makers from 
the macro- (national), meso- (local/regional), and micro-level (patient setting) were 
interviewed as well as two health economic experts. Decision-makers’ knowledge of 
economic evaluations was only modest, and their current use appeared to be limited. 
Nonetheless, decision-makers recognized the importance of economic evaluations 
and saw several opportunities for extending their use at the macro- and meso-level, 
but not at the micro-level. The disparity between the limited use and recognition of 
the importance of economic evaluations is likely due to the many barriers decision-
makers experience preventing their use. Such barriers include a lack of resources, 
methodological factors, lack of consensus-based willingness-to-pay thresholds, lack 
of relevant economic evaluations, public resistance, incentives to treat, ambiguity 
about the physicians’ responsibility for improving the efficiency of healthcare, and a 
limited ability to shift resources between sectors. Possible facilitators for extending 
the use of economic evaluations include educating decision-makers and the general 
population about economic evaluations, presenting economic evaluation results in 
a clearer and more understandable way, providing incentives for using economic 
evaluations, and improving the reliability, consistency, and transparency of eco-
nomic evaluations. ConClusions: This study demonstrated that the current use 
and impact of economic evaluations in Dutch healthcare decision-making is limited 
at best. Therefore, strategies are needed to overcome the barriers that currently pre-
vent economic evaluations from being used extensively, and recommendations will 
be provided as to what those strategies could be.
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objeCtives: The aim of this work is to evaluate the success rate of including 
medicinal products to the reimbursement system after the adoption of new drug 
legislation in December 2011. Methods: We assessed the inclusion of drugs to 
the reimbursement system based on data published on the Ministry of Health web-
site. We evaluated the success rate of reimbursement applications in the period 
from 1.1.2012 to 30.6.2015. We analysed separately the successful and unsuccess-
ful proceedings, the success rate of proceedings in individual therapeutic groups, 
as well as the development of the success rate of the inclusion of drugs over the 
monitored period. With unsuccessful proceedings, we assessed the shortcomings 
in pharmacoeconomic analyses given in the decisions. Results: In the evaluated 
period a total of 178 applications were registered for the inclusion of new drugs 
to the reimbursement system. Of these, 55 cases (30.9%) concerned drugs that in 
the Budget impact analysis showed the need for an increase in expenditure. In 79 
cases, a new active substance was included, with the remainder comprising fixed 
combinations, new strengths, forms and packaging. A total of 127 applications were 
successful (71.35%). In the case of applications with an budget impact, the success 
rate was 60%. In the case of unsuccessful submissions, in 58.8% the reason for non-
inclusion was the pharmacoeconomic analysis and the most common shortcomings 
concerned the selection of analysis (13.7%), selection of comparator (11.8%) and 
incorrect calculation of output parameters (11.8%). The highest inclusion success 
rate was seen for drugs in the ATC groups M, V and D, while the lowest was for drugs 
in groups H, L and S. ConClusions: The success rate for inclusion of new drugs is 
relatively high in Slovakia, but the majority of included drugs do not require higher 
healthcare expenditures. The most frequent reason for non-inclusion of a drug was 
shortcomings in the pharmacoeconomic analysis.
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objeCtives: To estimate the prevalence of health services use in Brazil. Methods: 
The protocol of present review is available at PROSPERO (CRD42015016648). A struc-
tured search for population-based surveys was performed in MEDLINE, EMBASE, 
Scopus, LILACS, SciELO and Brazilian theses repository. Selection of studies, data 
extraction and critical appraisal processes was completed by two independent 
reviewers. Methodological quality assessment included random sample, unbi-
ased sampling frame, sample size, standard for measures, unbiased assessors for 
outcomes, response rate, subgroup analysis and description of subjects. In STATA, 
results of similar studies were grouped in meta-analysis of random effects and 
their heterogeneity was investigated by a model of inverse variance. All results 
were stratified by recall period and health service (dental or medical consultation 
or hospitalization). Results: The search recovered 1,312 references. Fifteen articles 
and five national surveys were included. The studies presented good methodological 
quality. They were made between 1995-2015 and, mainly, in the southern region. 
829,941 people were interviewed about the use of dental services in the past 360 
days, of which 32% (95% CI 22.7-41.9%) responded positively. 70% (95% CI 64.9-75.1%) 
of 710,703 subjects visited a doctor in last 54 weeks. Finally, 10.4% (95% CI 9.5-11.3%) 
of 695,072 respondents report hospitalization in previous 12 months. All results were 
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objeCtives: The present study aimed at investigating the impact of mandatory 
clinical clerkship courses on fifth year pharmacy students’ attitudes and perceived 
barriers toward providing pharmaceutical care (PC). Methods: A cross-sectional 
survey was conducted among 5th year pharmacy students undertaking manda-
tory clinical clerkship in the University of Gondar, Ethiopia. A pharmaceutical care 
attitudes survey (PCAS) questionnaire was used to assess the attitude (14 items), 
commonly identified drug-related problem/s (1 item) during clerkships, and per-
ceived barriers (12 items) toward the provision of PC. Statistical analysis was con-
ducted on the retrieved data. Results: Among the total of 69 clerkship students, 
65 participated and completed the survey (94.2% response rate). Overall, 74.45% 
of participants had positive attitude toward PC provision. Almost all respondents 
agreed that the primary responsibility of pharmacists in the healthcare setting was 
to prevent and solve medication-related problems (98.5%), practice of PC was valu-
able (89.3%), and the PC movement will improve patient health (95.4%), respectively. 
Unnecessary drug therapy (43%), drug-drug interactions (33%), and non-adherence 
to medications (33%) were the most common drug-related problems identified in 
wards. Highly perceived barriers for PC provision included lack of a workplace for 
counseling in the pharmacy (75.4%), a poor image of pharmacist’s role in wards 
(67.7%), and inadequate technology in the pharmacy (64.6%). Lack of access to a 
patient’s medical record in the pharmacy had significant association (P< 0.05) with 
PC practice, performance of PC during clerkship and provision of PC as clinical 
pharmacists ConClusions: Students attending the new clinical pharmacy pro-
gram in Ethiopia have a good attitude toward pharmaceutical care. However, the 
barriers to pharmaceutical care need to be addressed by integrating PC provision 
with pharmacy practice.
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objeCtives: Aim of this research was to investigate ideal attribution with revealing 
the relevance between pharmacy attribution and patients’ outcomes. Methods: A 
self-completion questionnaire from composed of two forms of “Pharmacy attribute” 
and “Patients attribute” was delivered to 3321 pharmacies across Japan which agreed 
to join in January 2013. Pharmacy attribute: a number of pharmacist, prescription/
day, home-visiting patients/ month, cooperated medical facilities. Patients attribute: 
adverse drug event, change in prescription, change in adherence, finding of unused 
drugs, and change in the amount of unused drugs. We grouped by 2 indexes (a num-
ber of prescription/day/pharmacist as ‘work load’ and cooperated medical facilities 
as ‘positivity to cooperate’) to 4 groups. (Used SPSS ver.21) Results: Among 1,890 
community pharmacies data (collecting rate: 56.9%), we extracted answers to all 
the question items about community pharmacy attribute necessary for grouping. 
The 1,327 community pharmacies data was collected as the target (the number of 
patient data: for 4,947) for the analysis. The data of 1327 pharmacies showed the 
middle of attribution showed 20 prescriptions filled /day/pharmacist (work load) 
and 1 medical facility cooperated. The group of ‘Prescriptions≦20 and Cooperated 
facility> 1’ and the groups of ‘Prescriptions> 20 and Cooperated facility> 1’ 
changed in prescription(p< 0.003), changed in adherence(p< 0.001), find of unused 
drugs(p< 0.001), and decreased the amount of unused drugs (p< 0.001) more than 
others. There is no significant differences in adverse drug event. ConClusions: 
It was suggested that there was relationship between pharmacy attribution (work 
load/ positivity to cooperate) and patient’s outcomes on healthcare service of home-
visiting.
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objeCtives: This study was conducted to assess the knowledge, attitude and 
practice of community pharmacists (CPs) towards ADR reporting and monitor-
ing. Methods: A prospective cross sectional study was conducted at selected 
community pharmacies. Pharmacists at selected pharmacies were administered 
a questionnaire by research pharmacist and two weeks’ time was given to each 
pharmacist to complete the survey. Questionnaire was designed with various 
elements which can evaluate knowledge, attitude and practice of pharmacists 
towards ADR reporting. Results: A total of 256 community pharmacists were 
approached at selected community pharmacies per study criteria and were admin-
istered a questionnaire. Of 256, only 56 CPs (21.8%) responded to the survey. Of 56 
respondents, 37.5% were able to define ADR correctly, whereas 35.7% of pharmacists 
believed ADRs solely as allergic response. Only 46% of pharmacists could correctly 
identify potential risk factors responsible to cause ADRs and 57% of pharmacists 
were aware of the consequences of ADRs. Almost 93% of respondents admit that 
safety reporting is an important responsibility of pharmacist however, surprisingly 
almost 73.2% pharmacists were not aware of existing pharmacovigilance program 
in the country. As per 78.5% respondents ADR reporting in the community phar-
macies lead to additional workload. Looking at willingness to report, almost 50% 
of pharmacists expect incentives to get involve in the safety reporting and other 
50% feels it as professional responsibilities which do not require incentives. Among 
respondents only 20% of them had ever reported ADR to nearer national safety 
reporting centres. However, majority of CPs are interested to contribute for ADR 
reporting if appropriate training is provided. ConClusions: Majority community 
pharmacists do not possess required knowledge on ADR reporting, its importance 
and national safety reporting program. There is a strong need to implement edu-
cational and regulatory interventions periodically to improve the understanding of 
safety reporting among CPs.
“baseline” year served as control data. Results: There were 1500 intervention and 
286 control participants with mean age (sd) 72.75 (7.82) and 73.39 years (7.31), and 
past year fall rates of 22.8% and 21.8%, respectively. Males comprised 23.1% of the 
intervention group and 24.8% of the control group. Majority were of Chinese eth-
nicity (86.7% of intervention and 81.1% of controls). Improvements from baseline 
to 52 weeks were significantly better (p< 0.05) for intervention participants than 
controls for the Six Minute Walk Test, Step Test, Falls Efficacy Score and Life Space 
Assessment; Safer Score was significantly better on follow-up for the intervention 
group. There was no significant difference in the Berg Balance, Timed-Up-And-Go, 
Chair Rise and EQ-5d. Intervention participants had significantly fewer falls in the 
third quarter of follow-up (95%CI of the difference= 0.00,0.10). Multivariate results 
revealed that the intervention group had significantly fewer falls for the entire 
follow-up year (Odds Ratio = 0.75, 95%CI = 0.58,0.97). ConClusions: Results sug-
gest that the program improves physical performance and reduces the incidence of 
falls in the elderly. Residents may be empowered to take responsibility for prevent-
ing falls in their own community.
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objeCtives: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. Methods: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. Results: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2015), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. ConClusions: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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objeCtives: To understand how comparative effectiveness research (CER) is being 
used by US managed care plans and pharmaceutical benefit managers (PBMs) to 
control the growth of healthcare costs and ensure appropriate utilization of products 
by pharmacy and therapeutics (P&T) committees. Methods: Managed care (MC) 
medical and pharmacy directors (MDs+PDs) completed an online interactive survey. 
Topics included: advisor and plan information and current/future coverage of CER. 
The use of CER and evidence-based medicine (EBM) was evaulated using a 5-point 
likert scale (5= completely agreeing;1= completely disagreeing). Results: Fifty-four 
percent of respondents were MDs, the remainder mostly pharmacists. Most worked 
for a health plan (83.6%) and 39.6% of the plans were local; 35.4% national; and 25.0% 
regional. Public (Medicare and Medicaid) and private (Commercial) plans were rep-
resented. When asked to select the area emerging CER is expected to affect: value of 
care (29.8%), optimization/improvement of clinical guidelines (27.7%), appropriate-
ness of care (14.9%), pharmaceutical research and development (6.4%), medical and 
pharmacy benefit management (17.0%), and 4.3% uncertain. When asked about their 
agreement in “progress in obtaining usable information on CER of therapies” the 
results were slightly negative with 42.5% disagreeing (34%= somewhat,8.5%= com-
pletely), 38.3% agreeing (4.3%= completely,34%= somewhat), and 19.1% neutral. When 
asked if they expect their plan to use CER regularly in formulary decision making by 
2015, more than half (53.2%,14.9%= completely,38.3%= somewhat) agreed, 27.7% disa-
greed (23.4%= somewhat,4.3%= completely), and 19.1% were neutral. When asked 
to assess how “MC commonly using EBM today in coverage decision making” the 
results were more favorable with 79.2% agreeing (27.1%= completely,52.1%= some-
what); 14.6% neutral and 6.3% disagreeing (6.3%= somewhat,0%= completely). The 
most desired change to their plan’s/PBM’s P&T process was for increased use of CER; 
and a move toward contractual risk-sharing. ConClusions: Formulary decision 
making in P&T committees is making progress in the use of comparative effective-
ness research. Results suggest that the acceptance of evidence-based medicine is 
valuable even if not comparative.
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